Octogenarian Skateboarder Shreds Concrete in Spain’s Bilbao 

Skateboarder Juanjo Urbizu, 88, rides his skateboard in a bowl at the Etxebarria Skatepark in Bilbao, Spain, January 31, 2024. (Reuters)
Skateboarder Juanjo Urbizu, 88, rides his skateboard in a bowl at the Etxebarria Skatepark in Bilbao, Spain, January 31, 2024. (Reuters)
TT

Octogenarian Skateboarder Shreds Concrete in Spain’s Bilbao 

Skateboarder Juanjo Urbizu, 88, rides his skateboard in a bowl at the Etxebarria Skatepark in Bilbao, Spain, January 31, 2024. (Reuters)
Skateboarder Juanjo Urbizu, 88, rides his skateboard in a bowl at the Etxebarria Skatepark in Bilbao, Spain, January 31, 2024. (Reuters)

Grinning mischievously, Juanjo Urbizu dons a baseball cap, tucks his T-shirt neatly into his sweatpants and adjusts the velcro straps on his elbow pads before positioning his skateboard on the bowl's edge, ready for the "drop".

Other skaters, dressed in baggy streetwear, crane their necks while the sun casts long shadows over the graffiti-covered concrete.

Urbizu's attempt at a gnarly trick draws stares because the athlete is a sight to behold, wheeling around the unassuming skate park in northern Spain having just turned 88.

For the cheerful octogenarian, each skating session begins by carefully clearing the square bowl of pebbles to guarantee a smooth ride.

"My bones are special," he chuckles in Bilbao's working-class neighborhood of Begona. "Though I touch wood."

In a rapidly ageing country, where more than half the population is over 44, the demographic shift is increasingly becoming a topic of national debate. Economists fret over the welfare state's sustainability when government data shows there are 137 people aged 64 and older for every 100 under 16.

But Spain's generally warm climate is conducive to outdoor activities and studies have proven the importance of physical exercise in bettering the quality of life and reducing the risk of disease for the elderly.

Urbizu took up skateboarding aged 70, partly because it was cheaper than his beloved snow sports. He finds the extreme sport more than just a way to stay fit, also offering an escape from monotony.

"By breaking the routine, you bring something new to everyday life, and that gives you a sense of rest," he argues.

For other people his age considering taking up skateboarding, he advises do it little by little.

"Falls here are truly bad, much worse than in the snow. Anyone who does something like this should wear full protection."



Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
TT

Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.

The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.